Gatifloxacin combined regimen — Competitive Intelligence Brief

Gatifloxacin combined regimen (Gatifloxacin combined regimen) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fluoroquinolone antibiotic. Area: Infectious Disease.

phase 3 Fluoroquinolone antibiotic Bacterial DNA gyrase and topoisomerase IV Infectious Disease Small molecule

Target snapshot

Gatifloxacin combined regimen (Gatifloxacin combined regimen) — Institut de Recherche pour le Developpement. Gatifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible microorganisms.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Gatifloxacin combined regimen TARGET	Gatifloxacin combined regimen	Institut de Recherche pour le Developpement	phase 3	Fluoroquinolone antibiotic	Bacterial DNA gyrase and topoisomerase IV
Moxifloxacin (Topical)	Moxifloxacin (Topical)	University of California, San Francisco	marketed	Fluoroquinolone antibiotic	Bacterial DNA gyrase and topoisomerase IV
moxifloxacin 0.5% HCI ophthalmic solution	moxifloxacin 0.5% HCI ophthalmic solution	Allergan	marketed	Fluoroquinolone antibiotic	Bacterial DNA gyrase and topoisomerase IV
Moxifloxacin 0.5% ophthalmic solution	Moxifloxacin 0.5% ophthalmic solution	Johns Hopkins University	marketed	Fluoroquinolone antibiotic	Bacterial DNA gyrase and topoisomerase IV
Cravit-based sequential therapy	Cravit-based sequential therapy	National Taiwan University Hospital	marketed	Fluoroquinolone antibiotic (as part of sequential therapy regimen)	Bacterial DNA gyrase and topoisomerase IV
Intracameral Moxifloxacin 0.1%	Intracameral Moxifloxacin 0.1%	Suzan A Rattan	marketed	Fluoroquinolone antibiotic	Bacterial DNA gyrase and topoisomerase IV
Vigamox Eye Drops	Vigamox Eye Drops	Merck Sharp & Dohme LLC	marketed	Fluoroquinolone antibiotic	Bacterial DNA gyrase and topoisomerase IV

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fluoroquinolone antibiotic class)

1. Bayer · 4 drugs in this class
2. Allergan · 4 drugs in this class
3. Mackay Memorial Hospital · 2 drugs in this class
4. Indiana University School of Medicine · 2 drugs in this class
5. Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · 1 drug in this class
6. Daewon Pharmaceutical Co., Ltd. · 1 drug in this class
7. Connect Biopharma Australia Pty Ltd · 1 drug in this class
8. GlaxoSmithKline · 1 drug in this class
9. Global Alliance for TB Drug Development · 1 drug in this class
10. Fundacion Clinic per a la Recerca Biomédica · 1 drug in this class